New study links kidney cancer to increased risk of dangerous blood clotting

April 22, 2014

Dr. Marc Carrier has published a study in the Journal of Thrombosis and Haemostasis that identifies an increased risk of developing dangerous blood clotting in the veins (venous thromboembolism, or VTE) of people who have had surgery for kidney cancer (renal cell carcinoma) but whose tumours could not be fully removed because of spread to the veins (tumour thrombus). In the first study of its kind, Dr. Carrier and his team found that such patients are eight times more likely to develop VTE than cancer patients whose tumor did not move to the veins. These findings suggest that these cancer patients with residual tumor thrombus may benefit from drugs that reduce blood clotting as a way to prevent VTE.

Funders: The Ottawa Hospital Foundation and The University of Ottawa

About the Ottawa Hospital Research Institute
The Ottawa Hospital Research Institute (OHRI) is the research arm of The Ottawa Hospital and is an affiliated institute of the University of Ottawa, closely associated with the university’s Faculties of Medicine and Health Sciences. OHRI includes more than 1,700 scientists, clinical investigators, graduate students, postdoctoral fellows and staff conducting research to improve the understanding, prevention, diagnosis and treatment of human disease.

Media contact
Paddy Moore
Communications and Public Relations
Ottawa Hospital Research Institute
613-737-8899 x73687
613-323-5680 (cell)